Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 3c, Revenues Beat; Maintains FY20 EPS/Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 3c, Revenues Beat; Maintains FY20 EPS/Revenue Guidance

Amneal Reports Second Quarter 2020 Financial Results

August 6, 2020 6:00 AM EDT

  Q2 2020 Net Revenue of $465 million; GAAP Net Loss of $(12) million; Diluted Loss per Share of $(0.08)

Q2 2020 Adjusted Net Income (1) of $38 million; Adjusted EBITDA (1) of $101 million; Adjusted Diluted EPS (1) of $0.13

Maintaining 2020 Full Year Financial Outlook

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) announced its results today for the second quarter ended June 30, 2020.

Amneal executed well against our operational and strategic goals in the second quarter and, even in the face of COVID-related headwinds, delivered strong financial results, said... More